lncRNA RUNX1-IT1和miR-195在NSCLC组织中的表达及临床意义  

Expression and clinical significance of lncRNA RUNX1-IT1 and miR-195 in NSCLC tissues

作　　者：秦少文 张方琪 QIN Shaowen;ZHANG Fangqi(Department of Respiratory and Critical Care Medicine,General Hospital of Central Theater Command,Wuhan,Hubei 430070,China;Department of Respiratory and Critical Care Medicine,the 987th Hospital of the PLA Joint Service Support Force,Baoji,Shaanxi 721000,China)

机构地区：[1]中部战区总医院呼吸与危重症医学科,武汉430070 [2]中国人民解放军联勤保障部队第九八七医院呼吸与危重症医学科,陕西宝鸡721000

出　　处：《重庆医学》2024年第3期394-398,404,共6页Chongqing medicine

基　　金：联勤保障部队战勤部应用基础研究项目(CLB19J029)。

摘　　要：目的探讨长链非编码RNA(lncRNA)RUNX1-IT1和miR-195在非小细胞肺癌(NSCLC)组织中的表达及其意义。方法收集2017年5月至2019年5月于武汉某三级甲等医院接受手术治疗的106例NSCLC患者的NSCLC组织及癌旁组织,经实时荧光定量PCR(qPCR)检测lncRNA RUNX1-IT1和miR-195表达水平,分析其与临床病理特征及预后的关系。结果与癌旁组织比较,NSCLC组织lncRNA RUNX1-IT1表达水平明显升高(3.65±0.33 vs.1.04±0.09),miR-195表达水平明显降低(0.46±0.05 vs.1.06±0.11),差异有统计学意义(P<0.05)。lncRNA RUNX1-IT1高表达患者中有淋巴结转移(69.49%vs.29.79%)、TNM分期为Ⅲ~Ⅳ期(72.88%vs.51.06%)、低-中分化(50.85%vs.27.66%)的比例明显高于低表达患者(P<0.05);miR-195低表达患者中有淋巴结转移(74.14%vs.25.00%)、TNM分期为Ⅲ~Ⅳ期(86.21%vs.35.42%)、低-中分化(56.90%vs.20.83%)的比例明显高于高表达患者(P<0.05)。lncRNA RUNX1-IT1高表达患者2年总生存率为35.60%(21/59),低表达患者3年总生存率为64.40%(38/47);miR-195高表达患者3年总生存率为68.75%(33/48),低表达患者3年总生存率为31.25%(15/58)。多因素Cox回归分析结果显示,有淋巴结转移(HR=2.216,95%CI:1.614~4.037)、TNM分期为Ⅲ~Ⅳ期(HR=1.627,95%CI:1.369~3.162)、低-中分化(HR=1.948,95%CI:1.572~4.712)、lncRNA RUNX1-IT1高表达(HR=3.087,95%CI:1.228~4.086)、miR-195低表达(HR=3.227,95%CI:1.936~6.641)是NSCLC患者预后的独立危险因素(P<0.05)。结论lncRNA RUNX1-IT1高表达、miR-195低表达预示NSCLC患者预后较差。Objective To investigate the expression and significance of long noncoding RNA(lncRNA)RUNX1-IT1 and miR-195 in non-small cell lung cancer(NSCLC).Methods NSCLC tissues and adjacent tissues of 106 NSCLC patients who received surgical treatment in one of class A tertiary hospital from May 2017 to May 2019 were collected,and the expression levels of lncRNA RUNX1-IT1 and miR-195 were detected by real-time quantitative fluorescent PCR(qPCR),and its relationship with clinicopathological features and prognosis was analyzed.Results Compared with paracancerous tissue,the expression level of lncRNA RUNX1-IT1 in NSCLC tissues was significantly increased(3.65±0.33 vs.1.04±0.09),while the expression level of miR-195 was significantly decreased(0.46±0.05 vs.1.06±0.11).The difference was statistically significant(P<0.05).The proportion of patients with high expression of lncRNA RUNX1-IT1 had lymph node metastasis(69.49%vs.29.79%),TNM stageⅢ-Ⅳ(72.88%vs.51.06%),and low-moderate differentiation(50.85%vs.27.66%)were significantly higher than those with low expression(P<0.05);The proportion of patients with low expression of miR-195 with lymph node metastasis(74.14%vs.25.00%),TNM stageⅢ-Ⅳ(86.21%vs.35.42%),and low-moderate differentiation(56.90%vs.20.83%)was significantly higher than those with high expression of miR-195(P<0.05).The 2-year overall survival rate was 35.60%(21/59)in patients with high expression of lncRNA RUNX1-IT1,and 64.40%(38/47)in patients with low expression.The 3-year overall survival rate was 68.75%(33/48)in patients with high miR-195 expression and 31.25%(15/58)in patients with low miR-195 expression.Multivariate Cox regression analysis showed that there were lymph node metastasis(HR=2.216,95%CI:1.614-4.037),TNM stageⅢ-Ⅳ(HR=1.627,95%CI:1.369-3.162),low-moderate differentiation(HR=1.948,95%CI:1.572-4.712),high expression of lncRNA RUNX1-IT1(HR=3.087,95%CI:1.228-4.086),low expression of miR-195(HR=3.227,95%CI:1.936-6.641)were independent risk factors for prognosis in NSCLC patients(P<0.05).Conclusi

关 键 词：lncRNA RUNX1-IT1 miR-195 非小细胞肺癌 预后 临床意义 

分 类 号：R734.2[医药卫生—肿瘤]